EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity; How pharmacy deserts are putting the health of Black and Latino Americans at risk

Taking stock of the drug industry, from the lab to the medicine chest

November 10, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Paulo Amorim / VWPics via AP Images STAT+ | EU regulator recommends expanding diabetes drug Mounjaro's approval to include obesity The ruling from a committee of the European Medicines Agency now goes to the European Commission, which makes the final decision. By Andrew Joseph How pharmacy deserts are putting the health of Black and Latino Americans at risk As retail chains like CVS and Rite Aid shutter stores, people in predominantly Black and Latino neighborhoods are left without pharmacy access. By Anika Nayak Opinion: State and local governments across the country are sidelining science Science-based decision-making is under attack in states across the country, threatening your health, the environment, and the economy. By Jacob Carter and Martha Kinsella Listen: Lilly's obesity drug, the power of radiation, & a biotech implosion This week on the podcast, we discuss the approval of Eli Lilly's curiously named treatment for obesity. By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser